Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders

According to the World Health Organization, the major psychiatric and neurodevelopmental disorders include major depression, bipolar disorder, schizophrenia, and autism spectrum disorder. The potential role of inflammation in the onset and progression of these disorders is increasingly being studied. The use of non-steroidal anti-inflammatory drugs (NSAIDs), well-known cyclooxygenase (COX) inhibitors, combined with first-choice specific drugs have been long investigated. The adjunctive administration of COX inhibitors to classic clinical treatments seems to improve the prognosis of people who suffer from psychiatric disorders. In this review, a broad overview of the use of COX inhibitors in the treatment of inflammation-based psychiatric disorders is provided. For this purpose, a critical analysis of the use of COX inhibitors in the last ten years of clinical trials of the major psychiatric disorders was carried out

Zoledronic acid as a novel dual blocker of KIR6.1/2-SUR2 subunits of ATP-sensitive K+ channels: Role in the adverse drug reactions

Zoledronic acid (ZOL) is used as a bone-specific antiresorptive drug with antimyeloma effects. Adverse drug reactions (A.D.R.) are associated with ZOL-therapy, whose mechanics are unknown. ZOL is a nitrogen-containing molecule whose structure shows similarities with nucleotides, ligands of ATP-sensitive K+ (KATP) channels. We investigated the action of ZOL by performing in vitro patch-clamp experiments on native KATP channels in murine skeletal muscle fibers, bone cells, and recombinant subunits in cell lines, and by in silico docking the nucleotide site on KIR and SUR, as well as the glibenclamide site. ZOL fully inhibited the KATP currents recorded in excised macro-patches from Extensor digitorum longus (EDL) and Soleus (SOL) muscle fibers with an IC50 of 1.2 ± 1.4 × 10−6 and 2.1 ± 3.7 × 10−10 M, respectively, and the KATP currents recorded in cell-attached patches from primary long bone cells with an IC50 of 1.6 ± 2.8 × 10−10 M. ZOL fully inhibited a whole-cell KATP channel current of recombinant KIR6.1-SUR2B and KIR6.2-SUR2A subunits expressed in HEK293 cells with an IC50 of 3.9 ± 2.7 × 10−10 M and 7.1 ± 3.1 × 10−6 M, respectively. The rank order of potency in inhibiting the KATP currents was: KIR6.1-SUR2B/SOLKATP/osteoblast-KATP > KIR6.2-SUR2A/EDL-KATP >>> KIR6.2-SUR1 and KIR6.1-SUR1. Docking investigation revealed that the drug binds to the ADP/ATP sites on KIR6.1/2 and SUR2A/B and on the sulfonylureas site showing low binding energy <6 Kcal/mol for the KIR6.1/2-SUR2 subunits vs. the <4 Kcal/mol for the KIR6.2-SUR1. The IC50 of ZOL to inhibit the KIR6.1/2-SUR2A/B channels were correlated with its musculoskeletal and cardiovascular risks. We first showed that ZOL blocks at subnanomolar concentration musculoskeletal KATP channels and cardiac and vascular KIR6.2/1-SUR2 channels

Three-dimensional structure of human cyclooxygenase (hCOX)-1

The beneficial effects of Cyclooxygenases (COX) inhibitors on human health have been known for thousands of years. Nevertheless, COXs, particularly COX-1, have been linked to a plethora of human diseases such as cancer, heart failure, neurological and neurodegenerative diseases only recently. COXs catalyze the first step in the biosynthesis of prostaglandins (PGs) and are among the most important mediators of inflammation. All published structural work on COX-1 deals with the ovine isoenzyme, which is easier to produce in milligram-quantities than the human enzyme and crystallizes readily. Here, we report the long-sought structure of the human cyclooxygenase-1 (hCOX-1) that we refined to an R/Rfree of 20.82/26.37, at 3.36 Å resolution. hCOX-1 structure provides a detailed picture of the enzyme active site and the residues crucial for inhibitor/substrate binding and catalytic activity. We compared hCOX-1 crystal structure with the ovine COX-1 and human COX-2 structures by using metrics based on Cartesian coordinates, backbone dihedral angles, and solvent accessibility coupled with multivariate methods. Differences and similarities among structures are discussed, with emphasis on the motifs responsible for the diversification of the various enzymes (primary structure, stability, catalytic activity, and specificity). The structure of hCOX-1 represents an essential step towards the development of new and more selective COX-1 inhibitors of enhanced therapeutic potential

Functional 3-Arylisoxazoles and 3-Aryl-2-isoxazolines from reaction of aryl nitrile oxides and enolates: Synthesis and reactivity

Heterocyclic compounds are crucial starting reagents and intermediates, or they are direct precursors of target chemicals and/or bio-pharmacological active compounds. Today, they are used in the total synthesis of natural products, in drugs or herbicides, and agrochemical preparation. Developing synthetic strategies targeting isoxazoles is a recurrent aim in preparative chemistry. In particular, five-membered heterocycles such as isoxazoles and isoxazolines are easily formed in a two steps or by a 'one-pot' procedure, by reacting aryl nitrile oxides with a variety of enolates of carbonyl compounds (i.e., aldehydes, ketones, carboxylic acids), followed by aromatization. Such a methodology was found to be selective and versatile allowing the preparation of pharmacologically active isoxazoles in high yields. 1 Introduction 2 Preparation, Synthetic Applications, and Reactivity of 3-Aryl-5-hydroxy-2- isoxazolines and 3-Arylisoxazoles 3 Synthesis of 5-Alkyl-3-aryl-5-hydroxy-2- isoxazolines and 5-Alkyl-3-arylisoxazoles 4 Synthesis and Reactivity of 3,4-Diaryl-5-hydroxy-2-isoxsazolines and 3,4-Diarylisoxazoles 5 Synthesis and Reactivity of 3-Aryl-5-hydroxy-5-vinyl-2-isoxazolines and 3-Aryl-5- vinylisoxazoles 6 Synthesis of 3-Aryl-4-phenylisoxazole-5-carboxylic Acid 7 Conclusions 8 Experimental Methodologies. © Georg Thieme Verlag Stuttgart

Five-member-ring heterocycles by reacting enolates with dipoles

The synthetic utility of enolates in the heterocycles synthesis constitutes the main topic of this review. Appropriate enolates, in a number of synthetic approaches, are easily formed in situ from a variety of carbonyl compounds (aldehydes, ketones, amides, etc.) and used for the ring construction of (poly)substituted heterocycles. Often, the synthesis of five-membered rings such as isoxazoles, triazoles, pyrazoles, etc. has been performed by using these intermediates through a two-step or even by one pot procedures. The selectivity and the versatility of enolates intermediates will be discussed, with particular attention to those methodologies useful for preparation of heterocycle containing pharmacologically active molecule